#United States #New Haven #Clinical Trials #Trevi Therapeutics #Haduvio

Trevi Therapeutics Reports First Quarter 2025 Results

Trevi Therapeutics, Inc. has recently released its financial results for the first quarter of 2025, showcasing significant developments in its pipeline, particularly surrounding its investigational therapy Haduvio™.

Financial Overview

Trevi Therapeutics, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker TRVI, reported a net loss of $10.3 million for the first quarter, a slightly improved figure compared to the $10.9 million loss in the same period of the previous year. The company ended the quarter with $103.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations until the fourth quarter of 2026.

The research and development expenses saw a decrease to $7.8 million from $8.8 million, primarily due to reduced clinical development expenses. Meanwhile, the general and administrative expenses rose to $3.7 million, attributed to increased personnel costs.

Development and Trials

The company has been making significant strides in its clinical trials, particularly the Phase 2b CORAL trial, targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Enrollment was finalized in February 2025, with the last patient visit completed in April. Trevi anticipates topline results from this trial to be released in the second quarter of 2025.

In addition, the topline results from the Phase 2a RIVER trial were reported in March 2025. This trial involved patients with refractory chronic cough (RCC) and revealed a statistically significant reduction in cough frequency by 67% from baseline and 57% when adjusted for placebo. These promising results have encouraged Trevi to explore further trials for Haduvio’s effectiveness in chronic cough management.

Management Insight

Jennifer Good, President and CEO of Trevi Therapeutics, expressed optimism regarding the data from the RIVER trial. She noted that the results indicated the potential benefits of Haduvio, highlighting its mechanism which impacts the cough reflex in a unique manner. The management team is keen to build on the positive momentum and is focused on the pivotal data expected from the CORAL trial.

Importance of Haduvio

Chronic cough is a common symptom among IPF patients, with up to 85% of this population affected. Currently, there are no approved therapies available, which amplifies the significance of Trevi's ongoing research. Any advancements in treatment options could markedly improve the quality of life for these patients who often face debilitating effects and associated health risks due to persistent coughing.

Haduvio is designed to provide relief by acting on specific opioid receptors related to the cough reflex, making it a novel approach in managing chronic cough due to its dual mechanism of action as a kappa agonist and a mu antagonist. Given that chronic cough can severely impact patients’ lives, Haduvio’s innovative treatment could change the landscape of care for this under-addressed condition.

Looking ahead, Trevi Therapeutics is also preparing to showcase its progress and findings at several upcoming conferences, including the American Thoracic Society 2025 International Conference and the BIO International Convention, signaling its commitment to engaging with the scientific and medical communities.

Conclusion

As Trevi Therapeutics continues to develop Haduvio, the results from its ongoing trials will be crucial in validating its efficacy and moving closer to regulatory approval. The company's robust financial standing gives it the necessary backing to further its research endeavors, aiming to improve treatment paradigms for patients suffering from chronic cough.

For more updates, visit Trevi Therapeutics’ website.